Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
4.92 (1y: +43%)
Market Cap 588.7 M P/E(ttm)
Enterprise Value 603.46 M P/B
ARRY- NAS (USA)
Array BioPharma, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$4.92
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 0.967
ARRY's Cash to Debt is ranked higher than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ARRY: 0.967 )
ARRY' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 0.97
Equity to Asset -0.794
ARRY's Equity to Asset is ranked lower than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. ARRY: -0.794 )
ARRY' s 10-Year Equity to Asset Range
Min: -1.46   Max: 0.93
Current: -0.79
-1.46
0.93
F-Score: 1
Z-Score: -6.16
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -13.00
ARRY's Operating margin (%) is ranked higher than
65% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARRY: -13.00 )
ARRY' s 10-Year Operating margin (%) Range
Min: -410.1   Max: -13
Current: -13
-410.1
-13
Net-margin (%) -27.7
ARRY's Net-margin (%) is ranked higher than
62% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ARRY: -27.7 )
ARRY' s 10-Year Net-margin (%) Range
Min: -511.6   Max: -12.8
Current: -27.7
-511.6
-12.8
ROA (%) -21.8
ARRY's ROA (%) is ranked higher than
56% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARRY: -21.8 )
ARRY' s 10-Year ROA (%) Range
Min: -134.5   Max: -4.2
Current: -21.8
-134.5
-4.2
Revenue Growth (%) 23.5
ARRY's Revenue Growth (%) is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARRY: 23.5 )
ARRY' s 10-Year Revenue Growth (%) Range
Min: -18.2   Max: 28.3
Current: 23.5
-18.2
28.3
EBITDA Growth (%) -55.3
ARRY's EBITDA Growth (%) is ranked lower than
61% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARRY: -55.3 )
ARRY' s 10-Year EBITDA Growth (%) Range
Min: -55.3   Max: 69
Current: -55.3
-55.3
69
EPS Growth (%) -40.7
ARRY's EPS Growth (%) is ranked lower than
60% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARRY: -40.7 )
ARRY' s 10-Year EPS Growth (%) Range
Min: -40.9   Max: 39.4
Current: -40.7
-40.9
39.4
» ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ARRY Guru Trades in Q2 2012

Jim Simons 1,115,700 sh (+11.89%)
Louis Moore Bacon 100,000 sh (unchged)
Steven Cohen 41,769 sh (-0.61%)
» More
Q3 2012

ARRY Guru Trades in Q3 2012

Jim Simons 1,514,109 sh (+35.71%)
Steven Cohen Sold Out
Louis Moore Bacon 50,000 sh (-50%)
» More
Q4 2012

ARRY Guru Trades in Q4 2012

Paul Tudor Jones 26,200 sh (New)
Louis Moore Bacon Sold Out
Jim Simons 541,652 sh (-64.23%)
» More
Q1 2013

ARRY Guru Trades in Q1 2013

Steven Cohen 34,291 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 73,700 sh (-86.39%)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-12-31 Sold Out 0.0024%$1.77 - $2.83 $ 4.92116%0
George Soros 2011-12-31 Sold Out 0.0008%$1.77 - $2.83 $ 4.92116%0
George Soros 2011-09-30 New Buy$1.99 - $2.62 $ 4.92120%22400
George Soros 2011-06-30 Sold Out $2.06 - $3.21 $ 4.9282%0
Jean-Marie Eveillard 2011-06-30 Add 150%$2.06 - $3.21 $ 4.9282%250000
George Soros 2011-03-31 New Buy$2.7 - $3.29 $ 4.9264%14400
Jean-Marie Eveillard 2011-03-31 New Buy$2.7 - $3.29 $ 4.9264%100000
Jean-Marie Eveillard 2010-09-30 Sold Out 0.01%$2.67 - $3.44 $ 4.9263%0
Jean-Marie Eveillard 2010-06-30 Reduce -54.96%0.01%$2.66 - $4.02 $ 4.9244%450000
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/S 7.80
ARRY's P/S is ranked higher than
68% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ARRY: 7.80 )
ARRY' s 10-Year P/S Range
Min: 1.43   Max: 16.57
Current: 7.8
1.43
16.57
EV-to-EBIT 19.6
ARRY's EV-to-EBIT is ranked lower than
81% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. ARRY: 19.6 )
ARRY' s 10-Year EV-to-EBIT Range
Min: 6082.4   Max: 8002.5
Current: 19.6
6082.4
8002.5

Valuation & Return

vs
industry		 vs
history
Price/Median PS Value 1.3
ARRY's Price/Median PS Value is ranked higher than
62% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ARRY: 1.3 )
ARRY' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.3
Current: 1.3
0.3
2.3
Forward Rate of Return (Yacktman) -62.07
ARRY's Forward Rate of Return (Yacktman) is ranked lower than
57% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARRY: -62.07 )
ARRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -77.3   Max: -61
Current: -62.07
-77.3
-61

Business Description

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across a broad range of therapeutic areas. The Company is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib partnered with AstraZeneca, MEK162 partnered with Novartis, and danoprevir, an NS3 protease inhibitor, partnered with InterMune / Roche, having the potential to begin pivotal trials by the end of calendar year 2013. The Company's proprietary clinical programs include: ARRY-520, ARRY-614, ARRY-797, and ARRY-502. In addition, the Company has 10 partner-funded clinical programs, including two MEK inhibitors in Phase 2 clinical trials, selumetinib with AstraZeneca and MEK162 with Novartis. The Company also has a portfolio of proprietary and partnered drug discovery programs generated by its internal discovery efforts. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of pain and G-protein-coupled receptor 119 for the treatment of diabetes. The Company has collaborations with pharmaceutical and biotechnology companies under which it has out-licensed certain of its proprietary drug programs for further research, development and commercialization. The Company competes with companies worldwide that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:AR2.Germany
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
comment on ARRY Mar 02 2013 
Re: ARRY Aug 29 2011 
Drug Penny Stock Aug 23 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,309 Shares Jul 23 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK